Figure 1.
Figure 2.
Figure 3.
Difference in Blood Pressure After 12 Months of TKI Therapy Based on Drug Type
| Blood Pressure | Imatinib Adjusted Mean ± 95% CI | Nilotinib Adjusted Mean ± 95% CI | Between-Group Adjusted Difference ± 95% CI | p-value (adjusted) |
|---|---|---|---|---|
| SBP (mmHg) | 125 (123–127) | 132 (130–134) | 7 (4–10) | <0.001 |
| DBP (mmHg) | 81 (79–83) | 85 (83–87) | 4 (2–6) | 0.006 |
Study Characteristics
| Variable | Category | N = 148 | % |
|---|---|---|---|
| Gender | Male | 77 | 52 |
| Female | 71 | 48 | |
| Age | <50 years | 101 | 68.2 |
| ≥50 years | 47 | 31.8 | |
| Smoking Status | Yes | 18 | 12.2 |
| No | 130 | 87.8 | |
| Diabetes Mellitus | Yes | 7 | 4.7 |
| No | 141 | 95.3 | |
| Dyslipidemia | Yes | 5 | 3.4 |
| No | 143 | 96.6 | |
| TKI Type | Imatinib | 74 | 50 |
| Nilotinib | 74 | 50 |
Changes in Blood Pressure Before and After TKI Therapy
| TKI Type | BP Parameter | Baseline (median [range], mmHg) | 12 Months (median [range], mmHg) | 12-Month Adjusted Mean ± 95% CI (mmHg) | Patients ≥130/80 mmHg at 12 mo n (%)1 | p-value (adjusted)2 |
|---|---|---|---|---|---|---|
| Imatinib | SBP | 112 (90–131) | 125 (100–134) | 125 (123–127) | 28 (37.8%) | <0.001 |
| DBP | 72 (60–90) | 81 (70–97) | 81 (79–83) | 31 (41.9%) | <0.001 | |
| Nilotinib | SBP | 111 (100–126) | 130 (110–146) | 132 (130–134) | 41 (55.4%) | <0.001 |
| DBP | 70 (60–83) | 83 (70–100) | 85 (83–87) | 45 (60.8%) | 0.006 |